Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
3.40
-0.05 (-1.30%)
After Hours: 3.35 -0.05 (-1.62%)
Apr 24, 6:50PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.30 - 3.49
52 week 3.02 - 8.41
Open 3.46
Vol / Avg. 2.64M/7.37M
Mkt cap 662.90M
P/E     -
Div/yield     -
EPS -1.33
Shares 194.68M
Beta 2.28
Inst. own 79%
May 28, 2014
Exelixis, Inc. Annual Shareholder Meeting - 11:00AM EDT - Add to calendar
May 1, 2014
Q1 2014 Financial Results and Business Update Conference Call - 5:00PM EDT - Add to calendar
May 1, 2014
Q1 2014 Exelixis, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Mar 4, 2014
Exelixis, Inc. at Cowen Health Care Conference - Webcast
Feb 20, 2014
Q4 2013 Exelixis, Inc. Earnings Conference Call - Webcast
Feb 20, 2014
Q4 2013 Exelixis, Inc. Earnings Release
Feb 12, 2014
Exelixis, Inc. at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Exelixis, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1627.47% -781.03%
Operating margin -1369.08% -640.54%
EBITD margin - -626.57%
Return on average assets -49.75% -39.98%
Return on average equity -264.82% -134.98%
Employees 174 -
CDP Score - -

Address

210 E. GRAND AVE
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8377000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Frank L. Karbe Chief Financial Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Discovery Research, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Jeffrey J. Hessekiel J.D. Executive Vice President, General Counsel
Bio & Compensation  - Reuters
J. Scott Garland Executive Vice President, Chief Commercial Officer
Age: 44
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. Executive Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 63
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Carl B. Feldbaum Independent Director
Age: 70
Bio & Compensation  - Reuters